Singapore Teen Arrested for Selling Vapes, Products Sourced from Malaysia

Aug.20.2025
Singapore Teen Arrested for Selling Vapes, Products Sourced from Malaysia
A 19-year-old woman in Singapore was arrested after advertising vape sales on the messaging app WhatsApp. On August 19, she pleaded guilty to two charges, including possession of an imitation tobacco product and advertising the sale of vapes online.

Key Points:

  • Suspect: 19-year-old Albee Chai Buo Yin.
  • Charges: Possession of imitation tobacco products and advertising vape sales on WhatsApp.
  • Seized items: Six disposable vapes and one vape device fitted with a pod.
  • Sentencing progress: A probation suitability report has been ordered; sentencing is set for September 30. A third charge for the sale of three disposable vapes will be considered during sentencing.
  • Legal consequences: Possessing or using vapes carries a maximum fine of S$2,000. Distributing or selling them can result in up to six months’ imprisonment and a fine of up to S$10,000. If the vape pods contain etomidate, penalties can be as high as two years’ imprisonment and a fine of S$10,000.

 


 

According to The Straits Times on August 19, a Singapore teenager was arrested after advertising the sale of vapes on WhatsApp. On the same day, she admitted to two charges in court. The accused, Albee Chai Buo Yin, 19, was charged with possession of imitation tobacco products and with advertising vape sales online.

 

Case details showed that on October 24, 2024, Chai posted an advertisement on WhatsApp claiming she had various vape devices for sale. Following a tip-off, officers from the Health Sciences Authority (HSA) raided her Jurong West residence on December 19, 2024.

 

During the raid, officers seized six disposable vapes and one vape device fitted with a pod. Chai admitted that these devices were for her personal use. Investigations further revealed that she had helped friends purchase vapes, which were sourced from Johor Bahru, Malaysia, and delivered into Singapore.

 

The court has called for a probation suitability report, and Chai will return for sentencing on September 30. Another charge regarding her sale of three disposable vapes will be taken into consideration during sentencing.

 

Under Singapore law, possession, use, or purchase of vapes carries a maximum fine of S$2,000. Importing, distributing, or selling vapes and their components can result in up to six months in jail and a fine of up to S$10,000. Furthermore, if vape pods are found to contain etomidate, an anesthetic regulated under the Poisons Act, offenders may face up to two years’ imprisonment and a fine of up to S$10,000.

 

In July, Health Minister Ong Ye Kung announced that etomidate would soon be classified as a Class C controlled drug under the Misuse of Drugs Act (MDA) as an interim measure. Under the MDA, users may be subjected to supervision, mandatory rehabilitation programmes, or commitment to drug rehabilitation centres.

 

The government has also reminded the public that those who want to quit vaping can call the QuitLine (1800-438-2000) and join the Health Promotion Board’s “I Quit” programme without fear of prosecution, as participation in the programme does not presume prior use of vaping products. However, anyone caught possessing or using vapes will still face legal consequences.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore to Extend Etomidate Controls and Table New Vape Legislation in 2026
Singapore will maintain etomidate’s classification under drug control laws while preparing new legislation targeting e-vaporisers, as authorities reinforce a hardline regulatory stance on vaping.
Feb.05
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
TPB Q4 FY2025 Revenue Rises 29% to $121 Million; Modern Oral Business Up 266% Year Over Year
Turning Point Brands, a U.S. nicotine and tobacco-related consumer products company, reported its fiscal 2025 fourth-quarter results: quarterly revenue was $121 million, up 29% year over year; adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) was $30 million, up 14%. Net revenue from modern oral nicotine products was $41.3 million, up 266% year over year.
Mar.03 by 2FIRSTS.ai
Philippines DOH reiterates: vaping is not safer than smoking, citing irreversible health risks
Philippines DOH reiterates: vaping is not safer than smoking, citing irreversible health risks
The Philippine Department of Health reiterated Saturday that vaping should not be promoted as an alternative to cigarette smoking, Health Secretary Teodoro “Ted” Herbosa said in a radio interview, according to the Tribune. Herbosa said both vaping and smoking pose irreversible health risks and cited E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI), claiming it led to the death of a 22-year-old male with no smoking history in 2025.
Feb.28 by 2FIRSTS.ai
SICPA Secures Five-Year UK Vape Tax Stamp Contract
SICPA Secures Five-Year UK Vape Tax Stamp Contract
HM Revenue and Customs (HMRC) has awarded a five-year contract to Swiss technology company SICPA and Cartor Security Printers to implement the United Kingdom’s new vaping duty stamp and track-and-trace system, beginning in April 2026.
Market
Feb.24
FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA announced it will convene a Feb. 10, 2026 roundtable with small tobacco product manufacturers to gather feedback on PMTA submissions for ENDS products. The discussion will be viewable online, and a public docket is open for comments through March 12, 2026.
Feb.10 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11